Reference
[1] Tu H, Tu S, Gao S, Shao A, Sheng J. Current epidemiological and clinical features of COVID-19; a global perspective from China. J Infect 2020;81:1-9.
[2] Meo SA, Alhowikan AM, Al-Khlaiwi T, Meo IM, Halepoto DM, Iqbal M, et al. Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. Eur Rev Med Pharmacol Sci 2020;24:2012-2019.
[3] Liao H, Zhang L, Marley G, Tang W. Differentiating COVID-19 Response Strategies. The Innovation 2020;1:100003.
[4] World Health Organization. Coronavirus disease (COVID-19) situation reports -188. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Published 2020. Accessed 26 Jul 2020.
[5] Zhang XY, Huang HJ, Zhuang DL, Nasser MI, Yang MH, Zhu P, et al. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2. Infect Dis Poverty 2020;9:99.
[6] Wang YT, Landeras-Bueno S, Hsieh LE, Terada Y, Kim K, Ley K, et al. Spiking Pandemic Potential: Structural and Immunological Aspects of SARS-CoV-2. Trends Microbiol 2020;28:605-618.
[7] Liya G, Yuguang W, Jian L, Huaiping Y, Xue H, Jianwei H, et al. Studies on viral pneumonia related to novel coronavirus SARS-CoV-2, SARS-CoV, and MERS-CoV: a literature review. APMIS 2020;128:423-432.
[8] World Health Organization. Summary table of SARS cases by country, 1 November 2002 - 7 August 2003. https://www.who.int/csr/sars/country/2003_08_15/en/. Published 2003. Accessed 26 Jul 2020.
[9] World Health Organization. WHO MERS Global Summary and Assessment of Risk. https://www.who.int/emergencies/mers-cov/news-archive/en/. Published 2018. Accessed 26 Jul 2020.
[10] Gong Y, Ma TC, Xu YY, Yang R, Gao LJ, Wu SH, et al. Early Research on COVID-19: A Bibliometric Analysis. Innovation (N Y) 2020;1:100027.
[11] Kumar M, Taki K, Gahlot R, Sharma A, Dhangar K. A chronicle of SARS-CoV-2: Part-I - Epidemiology, diagnosis, prognosis, transmission and treatment. Sci Total Environ 2020;734:139278.
[12] Kim GU, Kim MJ, Ra SH, Lee J, Bae S, Jung J, et al. Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19. Clin Microbiol Infect 2020;26:948.e1-948.e3.
[13] Meng H, Xiong R, He R, Lin W, Hao B, Zhang L, et al. CT imaging and clinical course of asymptomatic cases with COVID-19 pneumonia at admission in Wuhan, China. J Infect 2020;81:e33-e39.
[14] World Health Organization. Coronavirus disease (COVID-19) situation reports -147. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Published 2020. Accessed 26 Jul 2020.
[15] Wu Y, Jing W, Liu J, Ma Q, Yuan J, Wang Y, et al. Effects of temperature and humidity on the daily new cases and new deaths of COVID-19 in 166 countries. Sci Total Environ 2020;729:139051.
[16] Morawska L, Tang JW, Bahnfleth W, Bluyssen PM, Boerstra A, Buonanno G, et al. How can airborne transmission of COVID-19 indoors be minimised? Environ Int 2020;142:105832.
[17] Correia G, Rodrigues L, Gameiro da Silva M, Gonçalves T. Airborne route and bad use of ventilation systems as non-negligible factors in SARS-CoV-2 transmission. Med Hypotheses 2020;141:109781.
[18] Ragia G, Manolopoulos VG. Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies. Eur J Clin Pharmacol 2020;76:1623-1630.
[19] Cadegiani FA, Goren A, Wambier CG. Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS). Med Hypotheses 2020;143:110112.
[20] Gao YM, Xu G, Wang B, Liu BC. Cytokine storm syndrome in coronavirus disease 2019: A narrative review. J Intern Med 2020:10.1111/joim.13144.
[21] Liu H, Liu F, Li J, Zhang T, Wang D, Lan W. Clinical and CT imaging features of the COVID-19 pneumonia: Focus on pregnant women and children. J Infect 2020;80:e7-e13. doi: 10.1016/j.jinf.2020.03.007.
[22] Ciceri F, Castagna A, Rovere-Querini P, De Cobelli F, Ruggeri A, Galli L, et al. Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy. Clin Immunol 2020;217:108509.
[23] Leung GM, Hedley AJ, Ho LM, Chau P, Wong IO, Thach TQ, et al. The epidemiology of severe acute respiratory syndrome in the 2003 Hong Kong epidemic: an analysis of all 1755 patients. Ann Intern Med 2004;141:662-673.
[24] Kulcsar KA, Coleman CM, Beck SE, Frieman MB. Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection. JCI Insight 2019;4:e131774.
[25] Qin W, Hu BZ, Zhang Z, Chen S, Li FJ, Zhu ZY, et al. [Clinical characteristics and death risk factors of severe COVID-19]. Zhonghua Jie He He Hu Xi Za Zhi 2020;43:648-653.
[26] Liu S, Luo H, Wang Y, Cuevas LE, Wang D, Ju S, et al. Clinical characteristics and risk factors of patients with severe COVID-19 in Jiangsu province, China: a retrospective multicentre cohort study. BMC Infect Dis 2020;20:584.
[27] Berenguer J, Ryan P, Rodríguez-Baño J, Jarrín I, Carratalà J, Pachón J, et al. Characteristics and predictors of death among 4,035 consecutively hospitalized patients with COVID-19 in Spain. Clin Microbiol Infect 2020;26:1525-1536.
[28] Selvin E, Juraschek SP. Selvin E, Juraschek SP. Diabetes Epidemiology in the COVID-19 Pandemic. Diabetes Care 2020;43:1690-1694.
[29] Zhu L, She ZG, Cheng X, Qin JJ, Zhang XJ, Cai J, et al. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metab 2020;31:1068-1077.e3.
[30] Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020;323:1239-1242.
[31] Dror AA, Eisenbach N, Taiber S, Morozov NG, Mizrachi M, Zigron A, et al. Vaccine hesitancy: the next challenge in the fight against COVID-19. Eur J Epidemiol 2020;35:775-779.
[32] Yang X, Liu Y, Liu Y, Yang Q, Wu X, Huang X, et al. Medication therapy strategies for the coronavirus disease 2019 (COVID-19): recent progress and challenges. Expert Rev Clin Pharmacol 2020;13:957-975.
[33] Ni L, Zhou L, Zhou M, Zhao J, Wang DW. Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19. Front Med 2020;14:210-214.
[34] Runfeng L, Yunlong H, Jicheng H, Weiqi P, Qinhai M, Yongxia S, et al. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacol Res 2020;156:104761.
[35] Guo C, Li B, Ma H, Wang X, Cai P, Yu Q, et al. Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm. Nat Commun 2020;11:3924.
Table 1 The classification of core keywords in 1991-2020
ACE2 angiotensin-converting enzyme 2, DPP4 dipeptidyl peptidase-4, TMPRSS2 transmembrane protease serine 2, SARSsevere acute respiratory syndrome, ORF open reading frame,Nsp non-structural protein, ADAM-17 a disintegrin and metalloproteinase 17, NK cell Nature Killer cell, NF-kappa B nuclear factor kappa-light-china-enhancer of activated B cells,TNF tumor necrosis factor, ARDS acute respiratory distress syndrome, COPD chronic obstructive pulmonary disease, CNScentral nervous system, rRT-PCR real-time reverse transcriptase-polymerase chain reaction, ELISA enzyme-linked immunosorbent assay
TP total publications, * author keywords mainly presented in 2020
Fig. 1 Global research outputs of Science Citation Index Expanded (SCIE),Social Science Citation Index (SSCI) and publications on coronavirus in 1991-2020
Fig. 2 Distribution changes of global publications in the coronavirus fields and the reported cases during three human coronaviruses outbreaks. (a) Distribution of publications in 1991-2002. (b) Distribution of publications in 2003-2011 and the world reported cases during the SARS outbreak. (c) Distribution of publications in 2012-2019 and the world reported cases during the MERS outbreak. (d) Distribution of publications in 2020 and the world reported cases during the COVID-19 outbreak
Fig. 3 International-collaborative and independent publications in coronavirus researches
IP independent publications, ICP international-collaborative publications, ICPP the percentage of international-collaborative publications
Fig. 4 Collaboration network of the productive countries or territories
(a) international collaboration in 1991-2019. (b) international collaboration in 2020